Precigen Inc (PGEN)

Precigen's stock has increased by 180.33% in the past six months. The FDA approval of PAPZIMEOS led to a surge in PGEN stock. Positive long-term follow-up data for PAPZIMEOS was announced. Precigen secured a $125 million non-dilutive credit facility. Precigen reported Q2 2025 earnings per share (EPS) of -$0.11, meeting estimates, and revenue of $0.86 million, which was above consensus estimates. Precigen completed a preferred stock offering, raising $87.5 million. Precigen insiders have sold significantly more company stock than they have bought.

Information regarding the specific demand seasonality for Precigen, Inc.'s products and services is not available. Demand for its products, once commercialized, would likely be driven by disease prevalence, treatment efficacy, regulatory approvals, and market access rather than traditional seasonal consumer patterns.

Precigen, Inc. is a biotechnology company focused on developing gene and cell therapies, operating in the healthcare sector, specifically in biotechnology and pharmaceutical preparations. The company develops next-generation gene and cell therapies for unmet medical needs in immuno-oncology, autoimmune disorders, and infectious diseases. The UltraCAR-T® Platform creates safer and more effective CAR-T cell therapies. The AdenoVerse™ Immunotherapy Platform uses adenovectors for gene delivery. The ActoBiotics Platform engineers live bacterial strains to deliver therapeutic payloads. Precigen also provides UltraPorator and develops research models and services. Formerly Intrexon Corporation, the company rebranded to Precigen, Inc. in February 2020.

Precigen, Inc. is headquartered in Germantown, Maryland, United States, and operates research and manufacturing sites in the United States and Europe. The company aims to expand its footprint in international markets with high demand for advanced biotherapeutics.

Precigen's brand reputation has been positively impacted by clinical and regulatory milestones. The FDA approval of PAPZIMEOS and positive long-term follow-up data have contributed to a favorable perception. Securing a $125 million non-dilutive credit facility signals financial stability. The overall sentiment is driven by the advancement of its therapeutic platforms and clinical pipeline.

As of recent data, 47.10% of Precigen's stock is held by insiders, and 33.51% is held by institutions. Addage Capital Partners significantly increased its stake in the company in September 2025.